Navigation Links
Reumofan Plus USA, LLC & Reumofan USA, LLC is Voluntarily Recalling all lots of Reumofan Plus Tablets Due to Undeclared Drug Ingredients
Date:2/15/2013

SPRINGFIELD, Pa., Feb. 15, 2013 /PRNewswire/ -- Reumofan Plus USA, LLC  and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol, dexamethasone, and diclofenac. Use of this product could result in serious and life-threatening injuries.   

Reumofan Plus is used as a treatment for muscle pain, arthritis, osteoporosis, bone cancer and other conditions. This product comes in thirty (30) tablet containers and is packaged in a green and gold box. Reumofan Plus was distributed nationwide through internet sales.

One illness has been reported to date in connection with this problem.

The recall was initiated after it was discovered that the product was distributed in packaging that did not reveal the presence of the active pharmaceutical ingredients, making it an unapproved drug.

Distribution of the product has been completely terminated by Reumofan Plus USA, LLC and Reumofan USA.

Consumers that have Reumofan Plus should be aware that the product may pose a serious health risk. Consumers who are taking these products or who have recently stopped taking Reumofan Plus should immediately consult a health care professional. Consumers who have purchased the thirty (30) tablet containers of Reumofan Plus are urged to return them, to; Reumofan Plus USA, LLC & Reumofan USA, LLC, 737 Buttonwood Drive, Springfield, PA 19064, where they will be exchanged for a new all-natural supplement of herbs only. This product was independently lab-tested to contain only all-natural herbs.

Consumers with questions may contact the company at (610) 544-9761, Monday thru Friday, between 10:00 a.m. and 2:00 p.m. EST.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

This recall is being conducted with the knowledge of the US Food and Drug Administration.

Contact:
Joseph McLean
(610) 544-9761


'/>"/>
SOURCE Reumofan USA, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 Research ... Market Size, Share, Development, Growth and Demand Forecast to 2022" report ... , , ... revenue of $6 billion in 2015, and it is expected to grow ... ultrasound segment is expected to witness faster growth during the forecast period, ...
(Date:12/2/2016)... December 2, 2016 On Thursday, ... honored excellence in research, development and innovation in the ... dinner was held in the presence of Sergey Tsyb, ... Russian Federation , Natalia Sanina, First Vice ... Murashko , Head of Roszdravnadzor, National Service of Control ...
(Date:12/2/2016)... 2, 2016 CVS Health Corporation (NYSE: ... in New York City on Thursday, December 15, 2016, beginning at 8:00 a.m. ... will provide an in-depth review of the company,s strategies ... company will also discuss 2017 earnings guidance during the ... the event will be broadcast simultaneously on the Investor ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel therapy ... MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason ... extensive financial and operational leadership experience to Advanced Inc. He began his career in ...
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... ... 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover ... he was inspired to practice medicine at an early age by his father, who ... making diagnoses and prescribing medicine,” he states. “It is about building relationships with people; ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet’s newest ... patients, standing as living proof that attitude and determination can combine into the ... that spike around the holidays. This campaign will offer patients a new-found hope, ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of American teens report ... parents report speaking with their child about sex related topics, less than 60 percent ... is proud to announce the launch of its second edition of the “Sexual Wellness” ...
Breaking Medicine News(10 mins):